CAV Regimen for R/R Ph- B-ALL

NARecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Acute Lymphoblastic Leukemia
Interventions
DRUG

cladribine, cytarabine,venetoclax

Cladribine 5 mg/m2/day, cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.

Trial Locations (1)

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
collaborator

Jining Medical University

OTHER

collaborator

The Second People's Hospital of Huai'an

OTHER

collaborator

The First Affiliated Hospital of Bengbu Medical University

OTHER

collaborator

Northern Jiangsu People's Hospital

OTHER

collaborator

Affiliated Hospital of Nantong University

OTHER

collaborator

Suzhou Hospital of Traditional Chinese Medicine

OTHER

lead

The First Affiliated Hospital of Soochow University

OTHER